Cox MMJ - Search Results

1

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older.

Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, Cox MMJ; PSC12 Study Team. Dunkle LM, et al. Among authors: cox mmj. N Engl J Med. 2017 Jun 22;376(25):2427-2436. doi: 10.1056/NEJMoa1608862. N Engl J Med. 2017. PMID: 28636855 Free article. Clinical Trial.

2

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.

Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Baxter R, et al. Vaccine. 2011 Mar 9;29(12):2272-8. doi: 10.1016/j.vaccine.2011.01.039. Epub 2011 Jan 28. Vaccine. 2011. PMID: 21277410 Clinical Trial.

3

Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial.

Dunkle LM, Izikson R, Patriarca PA, Goldenthal KL, Cox M, Treanor JJ. Dunkle LM, et al. Pediatrics. 2018 May;141(5):e20173021. doi: 10.1542/peds.2017-3021. Epub 2018 Apr 2. Pediatrics. 2018. PMID: 29610401 Clinical Trial.

4

FluBlok, a recombinant hemagglutinin influenza vaccine.

Cox MM, Patriarca PA, Treanor J. Cox MM, et al. Influenza Other Respir Viruses. 2008 Nov;2(6):211-9. doi: 10.1111/j.1750-2659.2008.00053.x. Influenza Other Respir Viruses. 2008. PMID: 19453397 Free PMC article. Review.

5

Randomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age.

Izikson R, Leffell DJ, Bock SA, Patriarca PA, Post P, Dunkle LM, Cox MM. Izikson R, et al. Vaccine. 2015 Nov 27;33(48):6622-8. doi: 10.1016/j.vaccine.2015.10.097. Epub 2015 Nov 1. Vaccine. 2015. PMID: 26529070 Clinical Trial.

6

Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.

Dunkle LM, Izikson R, Patriarca PA, Goldenthal KL, Muse D, Cox MMJ. Dunkle LM, et al. Among authors: cox mmj. J Infect Dis. 2017 Dec 5;216(10):1219-1226. doi: 10.1093/infdis/jix478. J Infect Dis. 2017. PMID: 28968871 Clinical Trial.

7

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.

Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Treanor JJ, et al. Vaccine. 2011 Oct 13;29(44):7733-9. doi: 10.1016/j.vaccine.2011.07.128. Epub 2011 Aug 9. Vaccine. 2011. PMID: 21835220 Clinical Trial.

8

Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.

Cox MM, Izikson R, Post P, Dunkle L. Cox MM, et al. Ther Adv Vaccines. 2015 Jul;3(4):97-108. doi: 10.1177/2051013615595595. Ther Adv Vaccines. 2015. PMID: 26478817 Free PMC article. Review.

9

Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.

Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F. Nachbagauer R, et al. mBio. 2016 Jan 19;7(1):e01996-15. doi: 10.1128/mBio.01996-15. mBio. 2016. PMID: 26787832 Free PMC article.

10

Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old.

Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, Cox MM. Keitel WA, et al. Vaccine. 2009 Dec 11;28(2):379-85. doi: 10.1016/j.vaccine.2009.10.037. Epub 2009 Oct 29. Vaccine. 2009. PMID: 19879222 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49 results

Search Page